Drug Coated Balloon (DCB) Family: An Innovation in Itself

An advanced medical device in cardiovascular and vascular interventions which precisely combine angioplasty with targeted drug delivery, ensuring long-term arterial health.

Why Concept Medical’s DCB Family?

Concept Medical’s DCB is the world’s first Sirolimus-coated balloon family, delivering targeted medication, minimizing restenosis and promoting faster recovery without permanent implants. 

Backed by clinical success, DCBs provide sustained blood flow and versatile treatment for conditions ranging from coronary artery disease to erectile dysfunction.

We Treat with DCB

Our innovative sirolimus-coated balloon effectively treats cardiovascular and vascular conditions like In-Stent Restenosis (ISR), Small Vessel Coronary Artery Disease, Peripheral Arterial Disease (PAD), Arteriovenous Fistula (AVF) and Grafts (AVG) and Erectile Dysfunction (ED). 

Drug Coated Balloon

Your Health, Our Innovations

Discover Concept Medical’s diverse range of Sirolimus Coated Balloon Products designed to enhance treatment outcomes and improve lives.
One Scroll = One Slide
Sirolimus-coated balloon for treating coronary artery disease, including In-Stent Restenosis, Small Vessels, Bifurcations lesions and De-Novo lesions. KNOW MORE
Sirolimus-coated balloon for stenotic lesions in dysfunctional AV fistulas or grafts for hemodialysis. KNOW MORE
Sirolimus-coated balloon for treatment of Vasculogenic Erectile Dysfunction. KNOW MORE
Sirolimus-coated balloon for peripheral arterial disease in SFA, popliteal, BTK, and iliac arteries. KNOW MORE

The Game Changer Sirolimus Coated Balloon

Left Image 1
Left Image 2
Left Image 3
Left Image 4
Right Image 1
Right Image 2
Right Image 3
Right Image 4

The Game Changer Sirolimus Coated Balloon

Left Image 1
Left Image 2
Left Image 3
Left Image 4
Right Image 1
Right Image 2
Right Image 3
Right Image 4

Redefining Your Recovery with  NANOLUTE TECHNOLOGY

Nanolute technology revolutionizes Sirolimus delivery by enhancing its lipophilicity and bioavailability, ensuring targeted treatment by reducing inflammation and minimizes the risk of restenosis for optimal patient outcomes. 

Nanolute

Nanolute Technology

Technology

Nanolute

Technology